Alnylam Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alnylam Pharmaceuticals Inc.
Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.
metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia explained their plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Regulus Therapeutics, Inc.
- Sirna Therapeutics, Inc. Alnylam U.S., Inc Ribopharma AG